Related Experiment Video

Updated: May 25, 2026

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
11:56

Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

Published on: October 25, 2013

Redesign of glycopeptide antibiotics: back to the future

Robert C James1, Joshua G Pierce, Akinori Okano

  • 1Department of Chemistry and The Skaggs Institute for Chemical Biology, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037, USA.

ACS Chemical Biology
|February 15, 2012
PubMed

Insights

New glycopeptide antibiotic derivatives are being developed to combat resistant bacteria like MRSA, VRE, and VRSA. This research aims to create powerful new treatments less susceptible to bacterial resistance.

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Drug Discovery

Background:

  • Glycopeptide antibiotics are crucial for treating resistant bacterial infections, including methicillin-resistant Staphylococcus aureus (MRSA).
  • The rise of vancomycin-resistant enterococci (VRE) and vancomycin-resistant Staphylococcus aureus (VRSA) poses a significant global health threat.
  • Limited development of new antibiotics exacerbates the challenge of combating resistant pathogens.

Purpose of the Study:

  • To review recent advancements in redesigning glycopeptide antibiotics.
  • To explore strategies for developing novel glycopeptide derivatives effective against resistant microbial infections.
  • To assess the future potential of these redesigned antibiotics in combating VRE and VRSA.

Main Methods:

  • Review of recent research on glycopeptide antibiotic modification.
  • Exploration of derivatization of natural glycopeptide products.
  • Consideration of chemical total synthesis approaches for novel glycopeptide structures.

Main Results:

  • Recent efforts focus on redesigning glycopeptide antibiotics to overcome existing resistance mechanisms.
  • Both modification of natural products and total synthesis are being pursued to create new derivatives.
  • The development of novel glycopeptides shows promise for treating infections caused by VRE and VRSA.

Conclusions:

  • Redesigned glycopeptide antibiotics offer a promising avenue for addressing the challenge of antimicrobial resistance.
  • Future development could yield a more potent class of antibiotics with reduced susceptibility to bacterial resistance.
  • Continued research is essential to translate these advancements into effective clinical treatments for resistant infections.

More Related Videos

Antibiotic Dereplication Using the Antibiotic Resistance Platform10:49

Antibiotic Dereplication Using the Antibiotic Resistance Platform

Published on: October 17, 2019

Production and Testing of Antimicrobial Peptides and Their Mimics10:35

Production and Testing of Antimicrobial Peptides and Their Mimics

Published on: April 10, 2026

Related Concept Videos

Inhibitors of Gram-positive Cell Wall Synthesis01:23

Inhibitors of Gram-positive Cell Wall Synthesis

Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
Inhibitors of Bacterial Protein Synthesis01:25

Inhibitors of Bacterial Protein Synthesis

Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
Production of Antibiotics01:27

Production of Antibiotics

Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
Peptidoglycan Synthesis01:28

Peptidoglycan Synthesis

Structure of PeptidoglycanPeptidoglycan is a vital structural component of the bacterial cell wall, providing mechanical strength and shape to the cell. It consists of repeating units of two sugars—N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM)—linked by β-1,4 glycosidic bonds. These sugar chains are cross-linked by short peptide chains, forming a mesh-like polymer that surrounds the bacterial plasma membrane.Cytoplasmic Phase – Precursor SynthesisPeptidoglycan biosynthesis begins in...